Navigation Links
Wistar Institute researcher receives 'New Innovator' award from NIH

A Wistar Institute researcher's novel approach to understanding genetic causes of human disease has earned him an NIH Director's New Innovator Award and grant from the National Institutes of Health.

Ken-ichi Noma, Ph.D., an assistant professor in Wistar's Gene Expression and Regulation Program, is working to develop a new method of mapping the three-dimensional structure of the human genome. These efforts aim to identify the molecular basis for many diseases, including cancers, and may aid in the development of new diagnostic tests and treatments.

New Innovator Awards support exceptionally creative scientists who take highly innovative and often unconventional approaches to major challenges in biomedical or behavioral research. Winners receive a grant of $1.5 million over five years to support their work. Only early-career investigators who have not yet received a major NIH grant are eligible. Noma is one of 31 researchers worldwide who received the grants this year.

"It's an honor to receive this award, which is a vote of confidence in my idea," Noma says. "The grant will allow me to pursue this line of research, which could have a huge impact. This work has the potential to elucidate an extremely important but poorly understood aspect of human disease."

The human genome exists in the cell nucleus as a complex, three-dimensional entity, the structure of which is disorganized in certain diseases, including cancers. However, it is unclear how the organization of the genome influences disease development. One impediment to understanding that process is an inability to accurately measure, in any given cell, the three-dimensional structure of the chromosomes that contain DNA. Noma proposes to develop a novel system for decoding that structure. Doing so could shed light on the molecular basis of numerous human diseases.

"Original, inventive ideas are what drive Wistar's lifesaving advances in biomedical research," notes Wistar President and CEO Russel E. Kaufman, M.D. "Dr. Noma exemplifies the energy and creativity that will lead to new solutions to today's major medical challenges.

His innovative approach to defining the structure of the human genome holds great potential for helping us understand the genetic basis of cancer and many other diseases."

Noma's work as a scientist has been marked by ingenuity. As a graduate student in the bioengineering department at Nagaoka University in Japan, he developed a strain of carrot that could grow in the desert. While a postdoctoral fellow in the lab of geneticist Shiv Grewal, Ph.D., at Cold Spring Harbor Laboratory, he mapped an uncharted region of the fission yeast genome and published the results in Science a notable feat for a fledgling researcher. He went on to further elucidate genome dynamics in fission yeast as a staff scientist at the National Cancer Institute's Laboratory of Biochemistry and Molecular Biology, where he worked prior to joining Wistar in September 2007. Noma's extensive research on yeast informs his current work with the human genome.

In announcing the New Innovator Awards, NIH Director Elias A. Zerhouni, M.D., said, "Nothing is more important to me than stimulating and sustaining deep innovation, especially for early career investigators and despite challenging budgetary times. These highly creative researchers are tackling important scientific challenges with bold ideas and inventive technologies that promise to break through barriers and radically shift our understanding."


Contact: Abbey J. Porter
The Wistar Institute

Related biology news :

1. Swiss Institute of Bioinformatics 10th Anniversary Conference
2. Syracuse University partners with Serum Institute of India to develop vaccines for children
3. Cornell gets $10 million NSF grant to establish new sustainability institute
4. Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT
5. NYU Cancer Institute researcher among first NIH EUREKA award recipients
6. Broad Institute awarded grant to develop chemical probes for human biology and disease
7. Broad Institute researchers introduce next generation tool for visualizing genomic data
8. Baker Institute report proposes strategies to ensure global energy security
9. New study spotlights National Institutes of Health grant outcomes for clinical research
10. UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech
11. New round of Environmental Venture Projects from Stanfords Woods Institute
Post Your Comments:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
Breaking Biology Technology: